

Second Supplemental Amendment  
U.S.S.N. 09/292,217  
Page 3 of 4

### REMARKS

Applicant amends claims 1 and 20. Accordingly, after entry of this Supplemental Amendment, claims 1, 2, 4-9, 12-24, 27 and 31- 37 will be pending for examination.

Independent claims 1 and 20 are amended to further clarify the claimed invention. Specifically, independent claims 1 and 20 are amended to recite a target antigen associated with cancer and expressed on a target cell in a solid tumor.


Support for these amendments can be found in the specification as filed, *inter alia*, on page 13, line 12 through page 14, line 4; page 15, lines 3-16; and in the Examples.

Applicant submits that no new matter is introduced by these amendments.

### CONCLUSION

Applicant submits that on the basis of the foregoing remarks and claim amendments, claims 1, 2, 4-9, 12-24, 27, and 31-37 are in condition for immediate allowance. Accordingly, Applicant respectfully requests entry as such. The Examiner is respectfully requested to call the undersigned at (617) 248-7240 prior to issuing a further Office action in this application, if necessary.

Respectfully submitted,



Patrick R.H. Waller, Ph.D.  
Attorney for the Applicant  
Reg. No. 41, 418

Date: November 1, 2002  
Testa, Hurwitz & Thibault  
125 High Street  
Boston, MA 02110  
(617) 248-7240

2524138\_1

Second Supplemental Amendment  
U.S.S.N. 09/292,217  
Page 4 of 4

**MARKED-UP VERSION OF AMENDED CLAIMS SHOWING AMENDMENTS**

1. (Four Times Amended) A method of inducing a cytotoxic immune response against a solid tumor in a mammal, the method comprising:

administering to a mammal a combination of (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen associated with cancer and expressed on a target cell in a solid tumor and interleukin 2, and (ii) an angiogenesis inhibitor having binding affinity for  $\alpha_v\beta_3$  integrin,

wherein the combination induces a cytotoxic immune response against the solid tumor that is greater than a response induced by the immunoconjugate alone.

20. (Four Times Amended) A composition for inducing an immune response against a solid tumor in a mammal, the composition comprising in combination:

(i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen associated with cancer and expressed on a target cell in a solid tumor and interleukin-2, and (ii) an angiogenesis inhibitor having binding affinity for  $\alpha_v\beta_3$  integrin,

wherein the combination induces a cytotoxic immune response against the solid tumor that is greater than a response induced by the immunoconjugate alone.